Form 4: Y-mAbs Therapeutics CEO Michael Rossi Receives Stock Options and Restricted Stock Units

Y-mAbs Therapeutics CEO Michael Rossi was granted 210,700 stock options and 105,300 restricted stock units on January 17, 2025, according to a recent SEC filing.

Summary

• Michael J. Rossi, the President and CEO of Y-mAbs Therapeutics, Inc., received 105,300 restricted stock units (RSUs) and 210,700 stock options on January 17, 2025.
• The RSUs will vest in three equal installments on January 17, 2026, 2027, and 2028, contingent upon Rossi's continued employment with the company.
• The stock options vest as to 25% on January 17, 2026, and then in equal monthly installments until fully vested, also contingent on continued employment.
• The stock options have an exercise price of $6.16 and expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
• The vesting schedule of the RSUs and stock options encourages long-term commitment from the CEO.

Risks

• The vesting of the RSUs and stock options is contingent on the CEO's continued employment, which could be a risk if he were to leave the company.

Industry Context

Equity compensation is a common practice for incentivizing executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• The vesting schedule of the options and RSUs is typical, with vesting occurring over several years to encourage long-term commitment.
• Companies like Amgen, Regeneron, and Gilead Sciences also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the CEO's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, executive compensation, insider trading, SEC Form 4, Y-mAbs Therapeutics, Michael Rossi